The US Food and Drug Administration (FDA) has approved methylnaltrexone bromide (Relistor, Salix Pharmaceuticals/Progenics Pharmaceuticals) subcutaneous injection 12 mg/0.6 mL for the treatment of opioid-induced constipation (OIC) in patients taking opioids for noncancer pain.

Click Here to read more